GLP-1 RA for Stage 1 Type 1 Diabetes
- Status
- Not yet recruitingResults none
- Why it is watched
- population of special interest (non-obese / healthy / non-diabetic)
- Who it enrolls
- age 12 Years to 70 Years; healthy volunteers accepted; no BMI minimum stated; conditions: Stage 1 Diabetes Mellitus, Type 1
- Interventions
- Semaglutide; Placebo
- Conditions
- Stage 1 Diabetes Mellitus, Type 1
- Phase and size
- Phase 2 · 15 participants
- Dates
- Start 2027-09-01
Primary completion 2029-06-01 - Sponsor
- Children's Hospital Medical Center, Cincinnati (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- C-peptide area under the curve12 months
- C-peptide area under the curve (AUC)12 months
02Eligibility
Who can take part
Inclusion Criteria: * Stage 1 Type 1 Diabetes * Screening OGTT with impaired or loss of first phase insulin secretion but no dysglycemia to suggest stage 2 or stage 3 type 1 diabetes Exclusion Criteria: * History of anaphylaxis or allergies to GLP-1 receptor agonists * Already on a GLP-1 receptor agonist * History of bariatric surgery * Personal or family history of cancer such as medullary thyroid cancer * Personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis * Severe hypoglycemia within 3 months of study enrollment * Pregnant, breastfeeding, or the intention of becoming pregnant or not using adequate contraceptive measures * Adult individuals with BMI \< 18.5 kg/m2 and pediatric participants with BMI \< 5th percentile
03Change log
Registry changes
No changes recorded since the trial was added.